These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12409224)

  • 1. In vitro and in vivo treatment of colon cancer by VIP antagonists.
    Levy A; Gal R; Granoth R; Dreznik Z; Fridkin M; Gozes I
    Regul Pept; 2002 Nov; 109(1-3):127-33. PubMed ID: 12409224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
    Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
    Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
    Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
    Gelber E; Granoth R; Fridkin M; Dreznik Z; Brenneman DE; Moody TW; Gozes I
    Cancer; 2001 Oct; 92(8):2172-80. PubMed ID: 11596035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
    Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
    Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
    Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
    Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.
    Dufes C; Alleaume C; Montoni A; Olivier JC; Muller JM
    J Mol Neurosci; 2003; 21(2):91-102. PubMed ID: 14593209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human neuroblastoma growth by a specific VIP antagonist.
    Lilling G; Wollman Y; Goldstein MN; Rubinraut S; Fridkin M; Brenneman DE; Gozes I
    J Mol Neurosci; 1994-1995; 5(4):231-9. PubMed ID: 7577366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
    Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
    Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.
    Balster DA; O'Dorisio MS; Albers AR; Park SK; Qualman SJ
    Regul Pept; 2002 Nov; 109(1-3):155-65. PubMed ID: 12409228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
    Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
    Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of tumor cell growth by vasoactive intestinal peptide.
    Scholar EM; Paul S
    Cancer; 1991 Mar; 67(6):1561-4. PubMed ID: 2001545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
    Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
    Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
    Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
    Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
    Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis.
    Zupan V; Hill JM; Brenneman DE; Gozes I; Fridkin M; Robberecht P; Evrard P; Gressens P
    J Neurochem; 1998 May; 70(5):2165-73. PubMed ID: 9572304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
    Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE
    J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.